Evidence map›Paper›PMID 21609764›Full record

ArticlePharmacological research2011

A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy.

Clara Sciorati, Daniela Miglietta, Roberta Buono, Viviana Pisa, Dario Cattaneo, Emanuele Azzoni, Silvia Brunelli, Emilio Clementi

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Pharmacological research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04630132 (Renal Ageing-sarcopenia Network), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04630132 unknown statusnot on this mapstarted 2017, after this paper: background citation

Renal Ageing-sarcopenia Network: a Combined Genetic, Immunological and Psychological Approach to Dissect Frailty

TypeobservationalSponsorIRCCS San RaffaeleRan2017 to 2021Enrolled1,500ConditionsAging, Frailty, Hypertension, CKD
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Redox Control of Skeletal Muscle Regeneration.Antioxidants & redox signaling · 2017
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Clara ScioratiSan Raffaele Scientific Institute, Division of Regenerative Medicine, Via Olgettina 58, 20132 Milan, Italy. sciorati.clara@hsr.it
Daniela Miglietta
Roberta Buono
Viviana Pisa
Dario Cattaneo
Emanuele Azzoni
Silvia Brunelli
Emilio Clementi
Neuroscience Institute · ITUniversity of Milan · ITUniversity of Milano-Bicocca · ITTethys Research Institute · ITVita-Salute San Raffaele University · IT

Funding

Telethon GGP07006
6 · The paper itself

Abstract

A resolutive therapy for muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration and in the severe forms to death, is still lacking. Since inflammation and defects in nitric oxide generation are recognized key pathogenic events in muscular dystrophy, we have analysed the effects of a derivative of ibuprofen, NCX 320, belonging to the class of cyclooxygenase inhibiting nitric oxide donator (CINOD), in the α-sarcoglycan null mice, a severe mouse model of dystrophy. NCX 320 was administered daily in the diet for 8months starting 1month from weaning. Muscle functional recovery was evaluated by free wheel and treadmill tests at 8months. Serum creatine kinase activity, as well as the number of diaphragm inflammatory infiltrates and necrotic fibres, was measured as indexes of skeletal muscle damage. Muscle regeneration was evaluated in diaphragm and tibialis anterior muscles, measuring the numbers of centronucleated fibres and of myogenic precursor cells. NCX 320 mitigated muscle damage, reducing significantly serum creatine kinase activity, the number of necrotic fibres and inflammatory infiltrates. Moreover, NCX 320 stimulated muscle regeneration increasing significantly the number of myogenic precursor cells and regenerating fibres. All these effects concurred in inducing a significant improvement of muscle function, as assessed by both free wheel and treadmill tests. These results describe the properties of a new compound incorporating nitric oxide donation together with anti-inflammatory properties, showing that it is effective in slowing muscle dystrophy progression long term. Of importance, this new compound deserves specific attention for its potential in the therapy of muscular dystrophy given that ibuprofen is well tolerated in paediatric patients and with a profile of safety that makes it suitable for chronic treatment such as the one required in muscular dystrophies.

Indexed as

AnimalsCell LineCyclooxygenase InhibitorsGene DeletionIbuprofenMiceMuscle, SkeletalMuscular Dystrophy, AnimalNitric OxideProstaglandin-Endoperoxide SynthasesSarcoglycans4-(nitrooxy)butyl 2-(4-isobutylphenyl)propanoateCyclooxygenase InhibitorsIbuprofenNitric OxideProstaglandin-Endoperoxide SynthasesSarcoglycans

Identifiers

PMID21609764
PMCPMC3134707
OpenAlexW1985183676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.